OncoMatch/Clinical Trials/NCT07451652

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Is NCT07451652 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Epcoritamab and Gemcitabine (1000 mg/m2) for relapsed/refractory diffuse large b cell lymphoma.

Phase 2RecruitingHospital Universitario Dr. Jose E. GonzalezNCT07451652Data as of May 2026

Treatment: Epcoritamab · Gemcitabine (1000 mg/m2) · Oxaliplatin — In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Cannot have received: autologous stem cell transplant

Cannot have received: allogeneic stem cell transplant

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify